---
pmid: '29519959'
title: P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances
  neuronal toxicity.
authors:
- Kalogeropulou AF
- Zhao J
- Bolliger MF
- Memou A
- Narasimha S
- Molitor TP
- Wilson WH
- Rideout HJ
- Nichols RJ
journal: Biochem J
year: '2018'
full_text_available: false
doi: 10.1042/BCJ20170699
---

# P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
**Authors:** Kalogeropulou AF, Zhao J, Bolliger MF, Memou A, Narasimha S, Molitor TP, Wilson WH, Rideout HJ, Nichols RJ
**Journal:** Biochem J (2018)
**DOI:** [10.1042/BCJ20170699](https://doi.org/10.1042/BCJ20170699)

## Abstract

1. Biochem J. 2018 Apr 9;475(7):1271-1293. doi: 10.1042/BCJ20170699.

P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that 
enhances neuronal toxicity.

Kalogeropulou AF(1), Zhao J(1), Bolliger MF(1), Memou A(2), Narasimha S(1), 
Molitor TP(1), Wilson WH(1), Rideout HJ(2), Nichols RJ(3).

Author information:
(1)Parkinson's Institute and Clinical Center, Sunnyvale, CA, U.S.A.
(2)Division of Basic Neurosciences, Biomedical Research Foundation of the 
Academy of Athens, Athens, Greece.
(3)Parkinson's Institute and Clinical Center, Sunnyvale, CA, U.S.A. 
jnichols@parkinsonsinstitute.org.

Autosomal-dominant, missense mutations in the leucine-rich repeat protein kinase 
2 (LRRK2) gene are the most common genetic predisposition to develop Parkinson's 
disease (PD). LRRK2 kinase activity is increased in several pathogenic mutations 
(N1437H, R1441C/G/H, Y1699C, G2019S), implicating hyperphosphorylation of a 
substrate in the pathogenesis of the disease. Identification of the downstream 
targets of LRRK2 is a crucial endeavor in the field to understand LRRK2 pathway 
dysfunction in the disease. We have identified the signaling adapter protein 
p62/SQSTM1 as a novel endogenous interacting partner and a substrate of LRRK2. 
Using mass spectrometry and phospho-specific antibodies, we found that LRRK2 
phosphorylates p62 on Thr138 in vitro and in cells. We found that the pathogenic 
LRRK2 PD-associated mutations (N1437H, R1441C/G/H, Y1699C, G2019S) increase 
phosphorylation of p62 similar to previously reported substrate Rab proteins. 
Notably, we found that the pathogenic I2020T mutation and the risk factor 
mutation G2385R displayed decreased phosphorylation of p62. p62 phosphorylation 
by LRRK2 is blocked by treatment with selective LRRK2 inhibitors in cells. We 
also found that the amino-terminus of LRRK2 is crucial for optimal 
phosphorylation of Rab7L1 and p62 in cells. LRRK2 phosphorylation of Thr138 is 
dependent on a p62 functional ubiquitin-binding domain at its carboxy-terminus. 
Co-expression of p62 with LRRK2 G2019S increases the neurotoxicity of this 
mutation in a manner dependent on Thr138. p62 is an additional novel substrate 
of LRRK2 that regulates its toxic biology, reveals novel signaling nodes and can 
be used as a pharmacodynamic marker for LRRK2 kinase activity.

Â© 2018 The Author(s). Published by Portland Press Limited on behalf of the 
Biochemical Society.

DOI: 10.1042/BCJ20170699
PMID: 29519959 [Indexed for MEDLINE]
